<div><div></div><div><span><p><span>Vincent LoPriore disclosed a 21.46% stake in Hepion Pharmaceuticals, Inc. through his direct holdings and affiliated entities. The Schedule 13D was filed on May 1, 2026. The position combines shares held by Gravitas Capital LP and the Invictus Capital Advisors Pension Plan, which LoPriore controls.</span></p><p><strong><span>Investor Intent</span></strong></p><p><span>LoPriore holds Hepion shares &#34;for investment purposes&#34; and &#34;may make further acquisitions of the Common Stock from time to time.&#34; He does not outline any plans to change control, push for board changes, or pursue strategic transactions at this time. The filing describes a straightforward investment stance, while leaving room for additional buying if conditions warrant. Investors may read this as a sizable insider-aligned position without an announced agenda.</span></p><p><strong><span>Investor's Background</span></strong></p><p><span>Vincent LoPriore serves as Executive Chairman of Hepion Pharmaceuticals, Inc. and is a U.S. citizen. He is the Managing Member of Gravitas Capital LP and the trustee and beneficiary of the Invictus Capital Advisors Pension Plan. He has the authority to vote and dispose of the shares held by Gravitas Capital LP and the pension plan.</span></p><p><span>Original SEC Filing: </span>Hepion Pharmaceuticals, Inc. [ HEPA ] - SCHEDULE 13D - May. 01, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

HEPA

LABU

<p>Vincent LoPriore has disclosed a 21.46% stake in Hepion Pharmaceuticals, Inc., filed on May 1, 2026. This stake includes shares from Gravitas Capital LP and the Invictus Capital Advisors Pension Plan, both controlled by LoPriore. He intends to hold these shares for investment purposes and may acquire more in the future, but has no current plans for control changes or board alterations. LoPriore is the Executive Chairman of Hepion and has voting authority over the shares.</p>

TradingView

Hepion Pharmaceuticals

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake